Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics Inc. is positioned favorably due to the promising advancements of zorevunersen, its lead drug candidate, which has demonstrated robust seizure reduction results and favorable safety profiles in Phase I/II studies. The anticipated revenue projections for zorevunersen have been increased, suggesting potential market valuations that could reach the low-$40s, particularly if the FDA accelerates its approval timeline. Additionally, the company's comprehensive approach to developing therapies targeting various haploinsufficiency diseases enhances its growth potential, indicating a solid foundation for future financial performance.

Bears say

Stoke Therapeutics has faced significant volatility, highlighted by a 15% decline in share value following market reactions to unrelated FDA filing strategies by another company, which may indicate broader investor concerns about its market positioning. The potential absence or dispute of a key patent raises substantial risks regarding the company's asset protection, which could lead to downward adjustments in valuation and financial projections. Additionally, despite the promise of its lead candidate, zorevunersen, the competitive landscape in the Dravet syndrome market, with existing therapies capturing substantial market shares, poses challenges to its adoption and long-term success.

STOK has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 8 analysts, STOK has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.